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Introduction:  The  complexity  of  immunity  to  malaria  is well  known,  and  clear  correlates  of  protection
against  malaria  have  not  been  established.  A  better  understanding  of  immune  markers  induced  by  can-
didate  malaria  vaccines  would  greatly  enhance  vaccine  development,  immunogenicity  monitoring  and
estimation of vaccine  efﬁcacy  in  the  ﬁeld.  We  have  previously  reported  complete  or partial  efﬁcacy
against  experimental  sporozoite  challenge  by  several  vaccine  regimens  in  healthy  malaria-naïve  sub-
jects  in  Oxford.  These  include  a prime-boost  regimen  with  RTS,S/AS02A  and  modiﬁed  vaccinia  virus
Ankara  (MVA)  expressing  the  CSP  antigen,  and  a DNA-prime,  MVA-boost  regimen  expressing  the  ME
TRAP  antigens.  Using  samples  from  these  trials  we performed  transcriptional  proﬁling,  allowing  a  global
assessment  of responses  to vaccination.
Methods:  We  used  Human  RefSeq8  Bead  Chips  from  Illumina  to  examine  gene  expression  using  PBMC
(peripheral  blood  mononuclear  cells)  from  16  human  volunteers.  To focus  on  antigen-speciﬁc  changes,
comparisons  were  made  between  PBMC  stimulated  with  CSP  or TRAP  peptide  pools  and  unstimulated
PBMC  post  vaccination.  We  then  correlated  gene  expression  with  protection  against  malaria  in  a  human
Plasmodium  falciparum  malaria  challenge  model.
Results: Differentially  expressed  genes  induced  by  both  vaccine  regimens  were  predominantly  in  the
IFN-  pathway.  Gene  set  enrichment  analysis  revealed  antigen-speciﬁc  effects  on  genes  associated  with
IFN  induction  and  proteasome  modules  after  vaccination.  Genes  associated  with  IFN  induction  and  anti-
gen  presentation  modules  were  positively  enriched  in subjects  with  complete  protection  from  malaria
challenge,  while  genes  associated  with  haemopoietic  stem  cells,  regulatory  monocytes  and  the myeloid
lineage  modules  were  negatively  enriched  in protected  subjects.
Conclusions:  These  results  represent  novel  insights  into  the  immune  repertoires  involved  in  malaria
vaccination.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Malaria remains one of the world’s greatest killers [1,2], and
a vaccine is urgently required. The complexity of immunity to
malaria is well known, and clear correlates of protection against
malaria have not been established. A better understanding of
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immune markers induced by candidate malaria vaccines would
greatly enhance vaccine development, immunogenicity monitor-
ing and estimation of vaccine efﬁcacy in the ﬁeld. Systems biology
approaches using gene expression proﬁling to identify early gene
signatures associated with vaccine immunogenicity are being pio-
neered for other pathogens [3–5].
The current leading vaccine against malaria is the RTS,S/AS01B
vaccine, a protein-in-adjuvant vaccine which targets the pre-
erythrocytic stage circumsporozoite protein. A phase three trial
showed an efﬁcacy against ﬁrst episode of clinical malaria of 46%
in children in the ﬁrst 18 months [6] with efﬁcacy in infants
was less at 27%. The predominant immune response induced is
http://dx.doi.org/10.1016/j.vaccine.2015.07.087
0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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antibodies [7,8] but vaccination mediated CD4+ T-cell responses
also occur [9–11].
We have previously reported complete or partial efﬁcacy against
experimental sporozoite challenge by several vaccine regimens in
healthy malaria-naïve subjects in Oxford. These include a prime-
boost regimen with RTS,S formulated with an alternative adjuvant
AS02A, and modiﬁed vaccinia virus Ankara (MVA) expressing the
CSP antigen [12], and a DNA-prime, MVA-boost regimen expressing
the ME  TRAP antigens [13]. Samples from these trials provided the
opportunity to perform transcriptional proﬁling, allowing a global
assessment of responses to vaccination.
A greater understanding of the immune response induced by
vaccines with partial efﬁcacy, and differences between responders
and non-responders is essential to allow further improvements in
vaccine design. This study presents results of transcriptional proﬁl-
ing of the malaria vaccine response in a series of early phase malaria
vaccine trials where vaccine efﬁcacy was assessed using a human
malaria challenge model. We  sought to identify key pathways
upregulated in response to vaccination with regimens targeting
the circumsporozoite protein (CSP) or the thrombospondin-related
adhesive protein (TRAP).
2. Materials and methods
2.1. Donors and clinical trials of candidate malaria vaccines
Samples used in the study came from healthy adult malaria-
naïve volunteers in Oxford, UK who participated in vaccine
trials as described previously [12,13]. The studies received eth-
ical approval from the Oxfordshire Research Ethics Committee,
Human Subjects’ Protection Committee at PATH (Program for
Appropriate Technology in Health) in Seattle, WA,  USA, the Naval
Medical Research Center Institutional Review Board and the U.S.
Navy Surgeon General in accordance with U.S. Navy regulations
(SECNAVINST 3900.39B) and in compliance with all applicable
U.S. Federal regulations governing the use of human subjects.
All participants gave written, informed consent prior to par-
ticipation. The trial was conducted according to Good Clinical
Practice guidelines, was externally monitored, and was  approved
by the UK Medicines and Healthcare products Regulatory Agency
(MHRA).
Subjects in the CSP study [12] received two intramuscular doses
of the RTS,S/AS02A vaccine (GlaxoSmithKline Biologicals, Rixensart,
Belgium) and one intradermal dose of 1 × 108 plaque forming units
(pfu) MVA-CS (Oxxon Therapeutics, Oxford, UK). RTS,S consists of
the carboxyl terminal (a.a. 207–395) of the 3D7 circumsporozoite
protein fused to the hepatitis B surface antigen, co-expressed in
yeast with the non-fused hepatitis B surface antigen. The propri-
etary adjuvant AS02A is an oil-in-water emulsion containing the
two immunostimulants QS21 and MPL. The vaccine was supplied as
a lyophilised pellet with separate adjuvant, and reconstitution gave
50 g of RTS,S with AS02A in one 0.5 ml  dose. MVA-CS is a recom-
binant virus using the viral vector modiﬁed vaccinia virus Ankara.
The insert sequence of MVA-CS encodes the entire 3D7 circum-
sporozoite protein, recoded to mammalian codon bias to facilitate
antigen expression. Four subjects studied received two  doses of
RTS,S/AS02A one month apart followed one month later by MVA-CS
(“RRM”), while four subjects received one dose of MVA-CS followed
at monthly intervals by two doses of RTS,S/AS02A (“MRR”). As no
signiﬁcant difference was observed in the original study for anti-
body responses, cellular responses or vaccine efﬁcacy [12] these
subjects are analysed as one group.
Subjects in the TRAP study [13] received two intramuscular vac-
cinations of 2 mg  of DNA-ME TRAP (Oxxon Therapeutics, Oxford, UK)
one month apart followed one month later by one intradermal
vaccination of 1.5 × 108 pfu MVA-ME TRAP (Oxxon Therapeutics,
Oxford, UK) one month later. ME TRAP is a multiple epitope
string including 14 CD8 T-cell epitopes, 1 CD4  T-cell epitope,
and 2 B-cell epitopes from six pre-erythrocytic Plasmodium fal-
ciparum antigens fused to the N terminus of TRAP as previously
described [14].
PBMC from eleven subjects in a third study [15] were used to
validate the gene expression changes by Q-PCR. Subjects in this
trial had received vaccination with FP9-ME TRAP (fowlpox virus 9,
Oxxon Therapeutics, Oxford, UK)) and MVA-ME TRAP.
The efﬁcacy of the vaccine schedules was  assessed by experi-
mental sporozoite challenge, whereby the volunteers were exposed
to the bites of ﬁve laboratory-reared mosquitoes infected with
the chloroquine-sensitive 3D7 strain of P. falciparum.  For the CSP
study, vaccinated subjects underwent sporozoite challenge along-
side ﬁve unvaccinated control subjects, 28 days after the ﬁnal
immunisation. In this study four out of twelve vaccinated sub-
jects demonstrated complete (sterile) protection against malaria
(no parasitaemia detectable within 21 days of challenge) and as
a group there was  a delay to parasitaemia compared to controls.
For the TRAP study eight vaccinated subjects underwent sporo-
zoite challenge alongside six unvaccinated control subjects, 14 days
after the ﬁnal immunisation. In this study one out of eight vacci-
nated subjects demonstrated complete (sterile) protection against
malaria and as a group there was a delay to parasitaemia compared
to controls. Across both studies all unvaccinated control subjects
developed slide-conﬁrmed malaria at a mean of 11.1 days (range
9–14 days).
2.2. Study design for gene expression proﬁling
The sixteen subjects studied by gene expression proﬁling in
this study are summarised in Table 1a and b. Eight subjects were
chosen from the CSP study and eight from the TRAP study. 14/16
underwent experimental sporozite challenge and all PBMC in this
study were drawn on the day of experimental sporozoite challenge
prior to challenge (28 days after ﬁnal vaccination for CSP study
and 14 days after ﬁnal vaccination for TRAP study). Each study
was analysed separately and then comparisons between the two
studies were made. The two  studies were then combined, with
gene expression signal for vaccine antigen-stimulated cells for each
sample normalised to its unstimulated pair.
2.3. Preparation of PBMC and cell stimulation
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient centrifugation, cryopreserved then thawed when
required as previously described [16]. PBMC were stimulated with
CSP (for the eight subjects in the CSP study) or TRAP (for the eight
subjects in the TRAP study) peptide pools for 12 h overnight at a
concentration of 2 g/ml. The CSP pool consisted of 61 15-mer pep-
tides and the TRAP pool consisted of 57 20-mer peptides. PBMC
incubated with media alone were control (unstimulated) cells.
After 12 h the cells were spun and resuspended in RLT buffer (Qia-
gen, Crawley, West Sussex, UK)  containing beta-mercaptoethanol
(VWR, Lutterworth, Leicestershire, UK).
2.4. Preparation of RNA for arrays
RNA extraction was  performed using the RNeasy Mini-kit kit.
(Qiagen, Crawley, West Sussex, UK)  according to the manufac-
turer’s instructions, including an on-column DNAse treatment. A
median of 0.37 g (range 0.19–0.52 g) RNA was obtained from
1 × 106 PBMC. RNA samples for arrays were ampliﬁed using the
Illumina TotalPrep RNA Ampliﬁcation kit (Ambion, Austin, TX)
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Table  1
Characteristics of the PBMC samples for gene expression.
(a)
Vaccine group Total Challenged Sterile protection by challenge No sterile
protection by
challenge
CSP 8 6 2 6
TRAP  8 8 1 7
Total  16 14 3 11
(b)
Subject Vaccine regimen Anti-CS antibody response
(g/ml)
Ex vivo ELISPOT 3rd Vac + 28
(SFC/106 PBMC)
Days post
vaccination
Protection against
challenge
CSP-1 RRM 22 6 14 Fully protected
CSP-2  RRM 30 51 14 Parasitaemia day
13.5
CSP-3  RRM 23 38 14 Parasitaemia day
12.5
CSP-4  RRM 50 8 14 Fully protected
CSP-5  MRR  98 75 14 Not challenged
CSP-6  MRR  5 28 14 Parasitaemia day
12.5
CSP-7  MRR  72 20 14 Not challenged
CSP-8  MRR  70 71 14 Parasitaemia day
12.5
Subject  Vaccine regimen Anti-TRAP antibody (geometric
mean titre relative to
pre-vaccination)
Ex vivo ELISPOT 3rd Vac + 14
(SFC/106 PBMC)
Protection against
challenge
TRAP-1 DDM-ME TRAP 83 14 28 Parasitaemia day 9
TRAP-2  DDM-ME TRAP 38 205 28 Parasitaemia day
12.5
TRAP-3  DDM-ME TRAP 51 468 28 Parasitaemia day
12.5
TRAP-4  DDM-ME TRAP 35 64 28 Parasitaemia day
14
TRAP-5  DDM-ME TRAP 409 341 28 Parasitaemia day
11
TRAP-6  DDM-ME TRAP 102 106 28 Parasitaemia day
12
TRAP-7  DDM-ME TRAP 92 749 28 Parasitaemia day
11.5
TRAP-8  DDM-ME TRAP 120 421 28 Fully protected
Part a shows the number of subjects whose PBMC samples were studied for gene expression proﬁling, and the number of subjects who  underwent sporozoite challenge. Part b
shows  the details of vaccine regimen, cellular immune response, antbody response, time of sample and results of sporozoite challenge for each subject. CSP = circumsporozoite
protein, TRAP = thrombospondin related adhesive protein, SFC/106 PBMC = spot forming cells per million peripheral blood mononuclear cells, R = RTS,S/AS02A vaccine,
M  = MVA-CS vaccine, RRM = two dose of RTS,S/AS02A vaccine followed by one dose of MVA-CS vaccine, MRR = one dose of MVA-CS vaccine followed by two doses of RTS,S/AS02A
vaccine. DDM-ME TRAP = two doses of DNA-ME TRAP followed by one dose of MVA-ME TRAP.
which is based on the Eberwine protocol [17] and incorporates
a Biotin-16-UTP label into the ampliﬁed RNA. RNA yield was
quantiﬁed using a NanoDrop ND 1000 Spectrophotometer (Nano-
Drop Technologies, Wilmington, DE)  and the quality of the samples
was checked as satisfactory using an Agilent Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA). Ampliﬁcation according to
the manufacturer’s instructions gave a median yield of 12.7 g
(range 2.0–35.9 g).
2.5. Microarray procedures
Ampliﬁed RNA (1 g per array) was hybridized to the Illu-
mina HumanRefSeq-8 BeadChip according to the manufacturer’s
instructions (Illumina, San Diego, CA, USA). The HumanRefSeq-8
bead chip comprises of 24,000 sequences representing 16,238
genes from the curated portion of the NIH Reference Sequence
Database http://www.ncbi.nlm.nih.gov/RefSeq/. Each sequence is
represented at least 30 times on the array. Arrays were scanned
with an Illumina bead array reader confocal scanner, accord-
ing to the manufacturer’s instructions. Array data processing and
preliminary analysis with background subtraction was performed
using Illumina BeadStudio software.
2.6. Gene expression data analysis
Gene expression analysis was performed using Genespring GX
version 7.3.1 (Agilent Technologies, Santa Clara, CA). Data were nor-
malised in Genespring GX by per chip to 50th percentile, per gene to
the median, and values less than 0.01 were reset to 0.01. For some
of the analysis samples were normalised per sample by normalis-
ing each stimulated sample to its unstimulated pair. Differential
expression was assessed on the Genespring normalised data by
Welch T-test, a parametric test not assuming equal variances, in
Genespring GX. Lists of differentially expressed genes between con-
ditions were analysed according to Gene Ontology (GO) categories
(Genespring) and using Pathway Express [18]. In the Pathway Express
program an enrichment analysis based on a hypergeometric distri-
bution identiﬁes pathways containing a proportion of differentially
expressed genes that is signiﬁcantly different from what is expected
by chance. A perturbation factor PF(g) is also calculated for each
gene on each pathway using the foldchange in gene expression and
the number and its position on the pathway. Correction for multiple
testing was using the False Discovery Rate method.
For analysis of protection against malaria, data on days to
parasitaemia was  used for all fourteen subjects who underwent
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Table 2
Genes differentially expressed in CSP-stimulated PBMC compared to unstimulated PBMC.
Gene name Description P value Median foldchange Minimum foldchange Maximum foldchange
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 0.00165 1.9 1.2 3.6
FY  Duffy blood group 0.00193 0.9 0.8 1.0
SOCS1  Suppressor of cytokine signaling 1 0.0022 1.5 1.1 2.9
IRF1  Interferon regulatory factor 1 0.00238 1.8 1.0 3.7
WARS  Tryptophanyl-tRNA synthetase 0.00278 2.3 1.1 7.8
P2RY6  Pyrimidinergic receptor P2Y, G-protein coupled 6 0.0028 1.5 1.1 3.5
IL4R  Interleukin 4 receptor 0.00285 1.4 1.0 1.8
CASP7  Caspase 7 apoptosis-related cysteine protease 0.00325 1.3 1.1 1.6
GBP5  Guanylate binding protein 5 0.00355 2.5 1.2 11.4
LAP3 Leucine aminopeptidase 3 0.00674 2.0 1.3 6.9
GBP4  Guanylate binding protein 4 0.0087 1.7 1.2 5.0
STAT1  Signal transducer and activator of transcription 1 0.00923 2.2 1.1 9.5
This is a selection of genes differentially expressed in the group of 8 CSP stimulated PBMC samples from the CSP study compared to the 8 unstimulated paired samples, from
the  post vaccination timepoint, analysed by Welch t-test, P < 0.01.
sporozoite challenge. A relative delay in time to parasitaemia com-
pared to unvaccinated control subjects or unprotected subjects
represents partial protection, as calculated by using highly sensi-
tive qPCR to estimate vaccine-induced reduction in the number of
parasites emerging from the liver [19]. For the purpose of analysis
fully protected subjects were designated as 21 days to parasitaemia
as follow-up ended at 21 days. Spearman’s rank correlation test in
Genespring was used to identify genes whose expression correlated
with protection against malaria by using days to parasitaemia as
a continuous parameter, with a two-tailed P < 0.01. In addition, for
gene set enrichment analysis (below), a comparison in gene expres-
sion was made for the three subjects completely protected against
malaria versus the eleven subjects who developed malaria. For this
analysis, each peptide stimulated PBMC sample was normalised to
its unstimulated pair prior to comparison.
Further statistical analysis was performed by Gene Set
Enrichment Analysis (GSEA), using the Molecular Signatures
Database, MSigDB http://www.broad.mit.edu/gsea/msigdb/index.
jsp [20]. This database is a collection of 1891 gene sets assem-
bled from a range of sources including online pathway databases,
PubMed literature and expert opinion. Brieﬂy, genes were ranked
according to their differential expression across two conditions and
the gene lists generated underwent GSEA analysis to quantify the
degree to which the database genesets occur towards the top (up-
regulated genes) or towards the bottom (down-regulated genes) of
the ranked list of genes from the experiment [21]. GSEA uses a vari-
ation of the Kolmogorov–Smirnov test (a statistical test of goodness
of ﬁt, and is better than the X2 test for small sample sizes) to give
an enrichment score for each geneset. The enrichment scores are
normalised for the size of the gene sets and correction for multiple
testing was by computing the Benjamini and Hochberg false dis-
covery rate [22]. Pathways up or down regulated were displayed by
modular mapping, whereby each gene set was assigned to a module
using online pathway databases and PubMed literature [23].
Raw data transcripts for all samples are available in Supplement
S1.
2.7. Real-time quantitative PCR (Q-PCR) analysis
Q-PCR was used to validate the array ﬁndings. Reverse transcrip-
tion of RNA into cDNA was performed using the Omniscript kit.
(Qiagen, Crawley, West Sussex, UK) according to the manufacturer’s
instructions. Quantitative real time Reverse Transcription PCR was
performed using the Lightcycler 2.0 (Roche, Basel, Switzerland)
carousel-based system using Quantitect SYBR Green Mastermix
(Qiagen, Crawley, West Sussex, UK). All reactions were performed
in duplicate with two negative controls per run. Data were pro-
duced as ampliﬁcation plots with ﬂuorescence plotted against
number of cycles. The CT (threshold cycle) value for each sample
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(a) Biological Process 
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Fig. 1. Gene Ontology processes involved in differentially expressed genes in CSP Study.
The  list of 744 genes identiﬁed as differentially expressed (Welch t-test, P < 0.05)
between the 8 CSP-stimulated PBMC samples and the 8 paired unstimulated samples
post vaccination by Welch t-test was used to generate pie charts of gene ontology
processes by biological process (a, all 744 genes) and immune response (b, 56 out
of  744 genes) in Genespring.
was calculated with the threshold set during the log-linear
phase of ampliﬁcation using the “Fit points” method. A selec-
tion of up-regulated and down-regulated genes was measured to
conﬁrm the array analysis, normalised to the housekeeping
gene HPRT. Differences between paired samples compared by
Wilcoxon’s signed rank test using Graphpad Prism version 5.0.
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Table  3
Genes differentially expressed in TRAP-stimulated PBMC compared to unstimulated PBMC.
Gene name Description P value Median foldchange Minimum foldchange Maximum foldchange
XKRY X Kell blood group
precursor-related, Y-linked
0.00159 1.16 1.04 1.33
HOM-TES-85 HOM-TES-85 tumor antigen;
Leucine zipper protein 4
0.0016 1.26 0.97 1.40
MCP-3  Monocyte chemotactic protein-3;
CCL7 Chemokine CC motif ligand 7
0.0018 4.24 0.36 15.74
PROC Protein C 0.00276 0.91 0.82 1.14
TCP11  T-complex homolog 0.00358 0.91 0.79 1.00
PLCL1 Phospholipase C-like 1 0.00427 0.93 0.81 1.14
SGK2  Serum/glucocorticoid regulated
kinase 2
0.00428 0.91 0.84 1.08
TSLP  Thymic stromal lymphopoietin
(stim DC maturation and Treg)
0.00462 0.91 0.83 1.14
CEACAM3 Carcinoembryonic antigen-related
cell adhesion molecule 3
0.005 1.24 1.12 1.38
GPR91  G protein-coupled receptor 91 0.00524 1.24 0.89 1.53
TGFBR1  Transforming growth factor, beta
receptor I (activin A receptor type
II-like kinase)
0.00587 0.95 0.84 1.08
RNF29  Ring ﬁnger protein 29 0.00587 0.98 0.86 1.07
MRGX1  G protein-coupled receptor MRGX1 0.00588 0.97 0.90 1.07
CD164  CD164 antigen, sialomucin 0.00662 1.00 0.93 1.05
LIMK2  LIM domain kinase 2 0.00675 2.84 0.84 4.39
ZFH4  Zinc ﬁnger homeodomain 4 0.00724 1.21 1.04 1.37
ICOSL  Inducible T-cell co-stimulator
ligand
0.00911 0.96 0.89 1.04
TGM2  Transglutaminase 2 (C polypeptide,
protein-glutamine-gamma-
glutamyltransferase)
0.00913 1.38 0.99 2.13
FOXP2  Forkhead box P2 0.00941 1.18 1.04 1.34
This is a selection of genes differentially expressed in the group of 8 TRAP-stimulated PBMC samples from TRAP study compared to the 8 unstimulated samples at the
post-vaccination timepoint 14 days after the ﬁnal vaccine, day of challenge (DOC), analysed by Welch t-test, P < 0.01.
3. Results
3.1. Antigen-speciﬁc changes in expression of genes from donors
vaccinated with RTS,S/AS02A and MVA-CS (CSP study)
Transcriptional proﬁles were compared in PBMC stimulated
with CSP and paired unstimulated PBMC in samples from eight vol-
unteers 28 days post-vaccination with RTS,S/AS02A and MVA-CS.
128 genes were differentially expressed with the signiﬁcance level
at P < 0.01 and 744 genes were differentially expressed with the
signiﬁcance level at P < 0.05. There was a predominance of genes
thought to be produced chieﬂy by monocytes in response to IFN-
including WARS,  IRF1 and STAT1.  The FY gene, known as the Duffy
antigen/receptor for chemokine (DARC) showed antigen-speciﬁc
down-regulation. A selection of differentially expressed genes is
shown in Table 2.
The differentially expressed genes in the CSP study were also
analysed by gene ontology process (Fig. 1) and by pathways
involved, where the pathways are ranked according to both the
number of genes present for each pathway compared to the
expected number for the total number of genes, and by the expres-
sion foldchanges of the genes. The top three pathways involved
were the antigen processing and presentation pathway (includ-
ing up-regulation of CD74, HLA-DPA1, TAP 1, TAP 2, and CIITA), the
Jak-STAT signalling pathway (including up-regulation of IFN- , IL-
15, IL-21R, IL-22, IL-26, IL-4R, JAK2, SOC1, SOC2 and STAT1 and the
Phosphatidylinositol signalling system (including down-regulation
of PIK3R1, PIK4CA and PIP5K1B).
3.2. Antigen-speciﬁc changes in expression of genes from donors
vaccinated with DNA-ME TRAP and MVA-ME TRAP (TRAP study)
Transcriptional proﬁles were compared in PBMC stimulated
with TRAP and paired unstimulated PBMC in samples from eight
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Fig. 2. Gene Ontology processes involved in PBMC differentially expressed genes, TRAP-
stimulated PBMC compared to unstimulated PBMCs post-vaccination. The list of 526
genes identiﬁed as differentially expressed (Welch t-test, P < 0.05) between the 8
TRAP-stimulated PBMC samples and the 8 unstimulated samples post vaccination by
Welch t-test was used to generate a pie chart of gene ontology processes by biological
process (all 526 genes) in Genespring. No GO processes for immune response were
signiﬁcant.
volunteers 14 days post-vaccination with DNA-ME TRAP and
MVA-ME TRAP. 86 genes were differentially expressed with the
signiﬁcance level at P < 0.01 and 526 genes were differentially
expressed with the signiﬁcance level at P < 0.05. A selection of the
genes with P < 0.01 is shown in Table 3. There was a remarkable
degree of overlap between the genes up-regulated by CSP stim-
ulation for CSP study PBMC and the genes up-regulated by TRAP
stimulation for TRAP study PBMC, such that 43 out of the 56 genes
(77%) up-regulated at least 1.5 fold in the CSP samples were also
up-regulated at least 1.5 fold in the TRAP samples.
5326 S. Dunachie et al. / Vaccine 33 (2015) 5321–5331
Table 4
Pathways involved in genes whose expression correlates with time to parasitaemia.
Rank Pathway name Impact
factor
#Genes in
pathway
#Input genes in
pathway
%Input genes in
pathway
%Pathway
genes in input
P-value
1 Leukocyte transendothelial
migration
7.273 116 6 2.597 5.172 6.94E − 04
2  Calcium signaling pathway 5.203 175 6 2.597 3.429 0.0055
3  Natural killer cell mediated
cytotoxicity
4.948 131 5 2.165 3.817 0.007099
4  Focal adhesion 4.694 195 6 2.597 3.077 0.009154
5  Jak-STAT signaling pathway 4.32 153 5 2.165 3.268 0.0133
6  Fc epsilon RI signaling pathway 3.465 75 3 1.299 4 0.031274
7  Phosphatidylinositol signaling
system
3.398 77 3 1.299 3.896 0.033438
8  Regulation of actin
cytoskeleton
3.162 208 5 2.165 2.404 0.042341
9  T cell receptor signaling
pathway
2.929 93 3 1.299 3.226 0.053438
10  GnRH signaling pathway 2.828 97 3 1.299 3.093 0.05916
Genes identiﬁed as showing expression correlating with number of days to parasitaemia in experimental sporozoite challenge by Spearman’s rank testing were analysed by
Pathway Express for linkage in the literature to biological pathways.
Table 5
Modular analysis of genes positively and negatively enriched.
Study Module Enrichment—% of
genes in module
Example genes Fold change
CSP study (CSP stimulated
versus unstimulated PBMC)
1. Interferon induced 30% positively enriched CCL8 CXCL10 WARS 2.6× up
2.4× up
2.3× up
2.  Adipocytes 29% positively enriched CD53 HCLS1 IFI30 1.3× up
1.3× up
1.2× up
TRAP  (TRAP stimulated versus
unstimulated PBMC)
1. Proteasome 72% positively enriched PSME1 PSMC3 ADRM1 1.4× up
1.3× up
1.2× up
2.  Interferon induced 30% positively enriched CCL8 WARS STAT1 5.6× up
3.0× up
2.7× up
Protection (3 subjects with
complete protection versus 11
subjects with malaria)
1. Interferon induced 32% positively enriched CXCL10
IFI35 TNFSF10
2.9× up
1.7× up
1.6× up
2.  Antigen presentation 14% positively enriched PLEK
HLA-DQA1 ICAM1
1.5× up
1.4× up
× up
1.  Haemopoetic stem cell 32% negatively
enriched
GNA15 DPYSL3 PDGF 1.6× down
1.4× down
1.3× down
2.  Regulatory monocytes 16% negatively
enriched
CXCL5 ABCG1 TRIP10 2.6× down
1.9× down
1.8× down
3.  Myeloid lineage 32% negatively
enriched
STAB1 TGFB1 CD59 1.7× down
1.5× down
1.4× down
Genes were ranked according to their differential expression across two conditions and the gene lists generated underwent Gene Set Enrichment Analysis (GSEA) to quantify
the  degree to which the database genesets occur towards the top (up-regulated genes) or towards the bottom (down-regulated genes) of the ranked list of genes from the
experiment. An enrichment score was assigned for each geneset using a variation of the Kolmogorov–Smirnov test and the enrichment scores were normalised for the size of
the  gene sets and correction for multiple testing by computing the Benjamini and Hochberg false discovery rate. Pathways up or down regulated were displayed by modular
mapping, whereby each gene set was assigned to a module using online pathway databases and PubMed literature.
The differentially expressed genes were also analysed by gene
ontology processes in Genespring (Fig. 2) and by pathways involved
in Pathways Express,  where the pathways are ranked as before
according to both the number of genes present for each pathway
compared to expected for the total number of genes, and by the
expression foldchanges of the genes. The top pathway identiﬁed
was the Antigen Processing and Presentation pathway (one gene
HLA-DQA2). The second ranked pathway was the Phosphatidyl-
inositol Signaling System (CALML3, PIP5K3, PLCE1 and SYNJ1) and
the third was the Colorectal Cancer-related pathway (including
ACVR1C, AKT2, FZD6, MSH2,  and TGFBR1)
3.3. Relationship between gene expression changes and
protection against experimental sporozoite challenge
Fourteen subjects underwent sporozoite challenge, with three
fully protected against malaria (two in the CSP study and one in the
TRAP study). A Spearman’s rank test was performed using all the
peptide stimulated PBMC samples (each normalised to its unstim-
ulated pair) from both the CSP and the TRAP study post-vaccination
treated as one experiment, and gene expression correlated with the
number of days to parasitaemia. 292 genes were identiﬁed (P < 0.01,
no genes identiﬁed after adjusting for multiple corrections). This
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Fig. 3. Modular representation of differentially expressed genes. (a) CSP. A number of modules were enriched in CSP-stimulated PBMC compared to unstimulated PBMC from
subjects  in the CSP study, including Interferon Induced and Adipocytes. No modules were negatively enriched. (b) TRAP. A number of modules were enriched in TRAP-stimulated
PBMC compared to unstimulated PBMC from subjects in the TRAP study, including Proteasome and Interferon Induced. No modules were negatively enriched. (c) Protection.
When the three subjects (two from CSP study, one from TRAP study) who did not develop malaria were compared to the eleven subjects who did develop malaria, a number
of  modules were both positively enriched (Interferon Induced and Antigen Presentation) and negatively enriched (Haemopoetic stem cell, Regulatory monocytes and Myeloid).
gene list was  analysed by Pathways Express and the top rank-
ing pathway was Leukocyte transendothelial migration (including
CLDN15, CYBB, PIK3R5, PRKCA, SIPA1 and VAV1) with the Calcium
Signalling Pathway and the Natural Killer Cell Mediated Cytotox-
icity pathway ranked second and third, respectively, as shown in
Table 4.
Because of the small numbers involved, it was difﬁcult to
look for the relationship between differential gene expression and
protection against malaria for the CSP and TRAP studies sepa-
rately. However it was noted that for the two subjects in the
CSP study with sterile protection against malaria, 703 genes were
differentially expressed at the signiﬁcance level at P < 0.05 com-
pared to the four subjects who developed malaria (comparing
CSP-stimulated PBMC normalised to each unstimulated pair),
including upregulation of IL17F, IGJ and IL13.
3.4. Modular approach to gene set enrichment analysis
To further explore the biological meaning of the differentially
expressed genes in this dataset, GSEA was performed (FDR 1%) and
genesets were classiﬁed into modules (Table 5 and Fig. 3). When
PBMC stimulated with peptides were compared to paired unstim-
ulated PBMC, a number of pathways were positively enriched,
but signiﬁcant downregulation of pathways was not seen. For
the CSP study, the module with the greatest enrichment was
Interferon induced (30% of all genes in the Interferon induced
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Fig. 4. Conﬁrmation of gene expression changes by Q-PCR. The expression levels of 5 genes were compared in TRAP stimulated and unstimulated PBMC in an independent set
of  samples from subjects in a different vaccine trial receiving a TRAP-containing regimen.
module were upregulated) followed by Adipocytes module (29% of
genes were upregulated). For the TRAP study there was  a marked
enhancement of the Proteasome module (72% of genes). The sec-
ond module with enhancement was Interferon induced (32% of
genes).
In order to facilitate identiﬁcation of pathways involved in pro-
tection against malaria, a comparison in gene expression was  made
for the three subjects completely protected against malaria versus
the eleven subjects who developed malaria. For this analysis, each
peptide stimulated PBMC sample was normalised to its unstimu-
lated pair prior to comparison. The top two modules upregulated
in protected subjects compared to unprotected subjects were Inter-
feron induced (27% of genes) and Antigen Presentation (14% of genes).
Three related modules were downregulated in protected subjects:
the HSC module (Haemopoetic stem cell, 32% of genes), Regulatory
Monocytes module (16% of genes) and Myeloid Lineage module (15%
of genes).
3.5. Conﬁrmation of expression changes by Q-PCR
The changes in expression of a selection of genes identiﬁed in
the array experiments were conﬁrmed by Q-PCR in an indepen-
dent dataset of eleven PBMC samples drawn from subjects who
had also received vaccine regimens encoding TRAP. For all 5 genes
checked, the same relationship of upregulation by TRAP stimula-
tion (for INDO, CCL8, CD209 and INHBA)  or downregulation (CCR2)
was conﬁrmed (Fig. 4).
4. Discussion
The aim of the gene expression studies was to exploit a
unique resource of samples from malaria vaccine trials to study
antigen-speciﬁc responses before and after vaccination. The avail-
ability of sporozoite challenge data allowed the opportunity to
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examine for relationships between expression changes and pro-
tection against malaria.
Many of the genes identiﬁed as upregulated and/or
differentially expressed such as CCL8, WARS (tryptophanyl-tRNA
synthetase), INDO (indoleamine 2,3-dioxygenase) and CXCL10
are known to be in the IFN- pathway and are thought to arise
predominantly from monocytes. Both pathway analysis and GSEA
with module allocation identiﬁed IFN induced genes as a theme
for response to CSP stimulation for CSP vaccinated subjects, for
response to TRAP stimulation for TRAP vaccinated subjects, and
a role in protection against malaria. This may  reﬂect a cascade of
events set in motion by antigen recognition by T-cells, representing
the activation of monocytes by antigen-speciﬁc IFN-. IFN- is well
established as a surrogate marker of T-cell immunogenicity by our
laboratory and others for both natural immunity against malaria
[24–26] and response to vaccination against malaria [13,27–29].
Interestingly IFN- itself did not always feature as differentially
expressed on the arrays, despite detection of up-regulation by
Q-PCR. This suggests that arrays have a lower dynamic range than
Q-PCR for the detection of fold change differences in expression.
In agreement with the results presented here, a study of gene
expression changes in both early malaria, using PBMC samples
from volunteers in a sporozoite challenge study, and in estab-
lished malaria in adults in Cameroon [30] showed induction of
IFN- pathways including STAT1 and JAK2 kinases in both groups
compared to malaria naïve subjects. Another study looked at gene
expression in Kenyan children with acute malaria [31], but studied
whole blood responses and most identiﬁed changes were linked
to erythrocytes and neutrophils. However up-regulation of IFN-
related genes such as HM74 and WARS was reported.
It was difﬁcult to detect signiﬁcant changes in gene expression at
the individual gene level. This is likely due to the small sample size
as only a low number of volunteers were vaccinated and challenged
in early phase clinical trials, where each regimen is unique. In addi-
tion, the impact of vaccination on global gene expression is likely to
be more subtle than malaria disease where an individual can have
chronic antigen exposure and a high parasite burden. However the
expression changes were conﬁrmed for all ﬁve genes examined in
samples from a different vaccine regimen trial. There was a substan-
tial overlap in results for both the CSP study and the TRAP study, for
example 77% of the genes up-regulated in the antigen-stimulated
PBMCs compared to unstimulated PBMCs post-vaccination in the
CSP study were up-regulated in the TRAP study. This is in spite of
different antigens and vaccine types, and lends cross-validity to the
ﬁndings.
The results give an insight into immune responses at a general
level across PBMCs. Many of the genes whose expression changes
following antigen stimulation are thought to arise from monocytes,
yet ﬂow cytometry analysis demonstrated that CD14+ cells com-
prised less than 6% of all cells (unpublished ﬁndings), thus exerting
a very dominant effect and being the responders for antigen recog-
nition upstream.
An antigen-speciﬁc up-regulation in IL-13 was  observed post-
vaccination in the two CSP study subjects who were completely
protected against malaria following vaccination with the antibody-
inducing vaccine RTS,S/AS02A along with MVA-CS. An association
between an IL-13 polymorphism linked with higher IL-13 levels
and protection against severe malaria has been reported [32], and
case-control studies in Gabon have suggested a role for IL-13 in
the control of malaria infection, speculatively by acting alongside
IL-4 to provide B cell help in switching to speciﬁc IgG1 antibody
production [33]. IL-13 was up-regulated in the TRAP subjects,
although the TRAP regimen is primarily an inducer of cellular
immunity. Expression of IL13AR2 was associated with longer days
to parasitaemia.
At the pathways level changes in antigen presentation and
processing, the Jak–Stat pathway and the phosphatidylinositol
signalling system emerged as the key pathways invoked by antigen
stimulation after vaccination. The presence of the colorectal can-
cer pathway is explained by the non-speciﬁc inﬂammatory genes
involved such as ACVR1C, AKT2, FZD6, MSH2,  and TGFBR1. For the
CSP study a number of upregulated genes corresponded to the
Adipocytes module, which features many immune related genes
including CD53, HCLS1 and IFI30.
It is of interest that subjects vaccinated with TRAP contain-
ing regimens showed a marked enrichment in activity of genes
related to the proteasome. A gene expression study of 39 sub-
jects receiving RTS,S vaccine reported upregulation of genes in
the proteasome degradation pathway (PSME2, PSMB9, PSMB6,and
PSMA4) to be associated with protection [34]. Similar strong induc-
tion of the proteasome module has been reported in a whole-blood
transcriptome study of P. falciparum-infected West African children
alongside a Plasmodium chabaudi mouse model [35]. The protea-
some plays a central role in MHC  peptide processing and antigen
presentation [36] and vaccine strategies that promote activation of
the proteasome should be pursued.
Sterile protection against malaria was  associated with positive
enrichment of genes associated with IFN induction and antigen
presentation modules, and negative enrichment of genes associ-
ated with haemopoietic stem cells, regulatory monocytes and the
myeloid lineage modules. The downregulation of stem cell pre-
cursors and myeloid lineage is compatible with recent literature
showing a correlation between low ratio of monocyte to lympho-
cyte count in the differential blood count of African children and
both improved response to RTS,S vaccine [37] and decreased sus-
ceptibility to malaria [38].
For the analysis of protection against malaria challenge, we
acknowledge the limitations of combining results from the two
different vaccine studies. However because of the small numbers
involved in these studies and the limited existing published data we
combined the two  studies to seek to identify the common themes
associated with protection from infection by candidate malaria vac-
cines. It is reasonable to assume that the complete sterile protection
in all three cases was due to vaccine-induced changes, because his-
torically all unvaccinated control subjects have become infected
upon sporozoite challenge. Our experimental design using anti-
gen stimulation allowed us to focus on vaccine-speciﬁc changes.
We analysed each of the two  regimens separately, and then looked
for common themes between the two  regimens. There was a sur-
prisingly high degree of overlap in differentially expressed genes
in response to stimulation with the vaccine antigens between the
two studies and we therefore believe combing the two studies is
justiﬁed.
The results of these array experiments conﬁrm and extend
existing published transcriptomics studies of response to infec-
tion and vaccination. A study of transcriptional changes in PBMCs
following vaccination with smallpox, vaccination with yellow
fever or natural upper respiratory tract infection [39] reported
up-regulation of many IFN-stimulated genes with a particular
predominance of genes involved in proteolysis and antigen pre-
sentation such as CD74 and LAP3. Another study of transcriptome
changes in PBMC in response to yellow fever vaccination con-
ﬁrmed upregulation of IFN-induced and anti-viral genes [4]. A
small study examining antigen-speciﬁc responses to inﬂuenza
vaccination also reported activation of pathways relating to
IFN- and antigen presentation [40]. A larger study of transcrip-
tome changes in PBMC following inﬂuenza vaccination compared
to baseline showed induction of IFN-related genes by a live
attenuated inﬂuenza vaccine but not by an inactivated vaccine
[3].
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5. Conclusions
The samples from two malaria vaccine trials have offered the
opportunity to proﬁle antigen-speciﬁc responses at the transcript
level. The ﬁndings conﬁrm and extend knowledge on responses to
vaccination and infection at the molecular level, and are informa-
tive in elucidating which pathways vaccination strategies target.
Vaccine strategies that enhance activation of the proteasome and
promote a switch towards lymphoid lineage are likely to be impor-
tant. Further studies in larger datasets will consolidate these
ﬁndings.
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